• Vaccine Name: CAdVax-RVFV glycoprotein
• Target Pathogen: Rift Valley Fever virus
• Target Disease: Rift valley fever
• Vaccine Ontology ID: VO_0004642
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001086
• Preparation: RVFV glycoprotein genes were incorporated into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a RVFV vaccine (Holman et al., 2009).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: The mice were injected intraperitoneally (i.p.) with 1 × 10^8 PFU (1 × 10^10 total viral particles) of CAdVax-RVF or control CAdVax-D on week 0. CAdVax-D is a vector with a backbone identical to that of CAdVax-RVF that expresses dengue virus glycoproteins (22). Some mice also received booster vaccinations of the same dose on week 10 (Holman et al., 2009).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Vaccinated and control animals were inoculated with 100 PFU of the ZH501 strain of RVFV by i.p. injection (Holman et al., 2009).
• Efficacy: Vaccinated mice were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector (Holman et al., 2009).